1-7 of 7
Geoffrey T. Gibney
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract B047: Monitoring treatment response and toxicity in BRAF V600-mutant metastatic melanoma with circulating cell-free DNA

Sidharth S Jain, A. Patrick IV McDeed, Megan E McNamara, Amber R Alley, Dori S Rosenstrauch, Harry Sun, Natalie Thompson, John M Kirkwood, Geoffrey T Gibney, Michael B Atkins, Anton Wellstein
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (21_Supplement): B047.
https://doi.org/10.1158/1557-3265.LIQBIOP24-B047
Published: 13 November 2024
View articletitled, Abstract B047: Monitoring treatment response and toxicity in BRAF V600-mutant metastatic melanoma with circulating cell-free DNA
Journal Articles

First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response

Timothy A. Yap, Justin F. Gainor, Margaret K. Callahan, Gerald S. Falchook, Russell K. Pachynski, Patricia LoRusso, Shivaani Kummar, Geoffrey T. Gibney, Howard A. Burris, Scott S. Tykodi, Osama E. Rahma, Tanguy Y. Seiwert, Kyriakos P. Papadopoulos, Mariela Blum Murphy, Haeseong Park, Amanda Hanson, Yasmin Hashambhoy-Ramsay, Lara McGrath, Ellen Hooper, Xiaoying Xiao, Heather Cohen, Martin Fan, Daniel Felitsky, Courtney Hart, Rachel McComb, Karen Brown, Ali Sepahi, Judith Jimenez, Weidong Zhang, Johan Baeck, Haley Laken, Richard Murray, Elizabeth Trehu, Christopher J. Harvey
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (17): 3695–3708.
https://doi.org/10.1158/1078-0432.CCR-21-4256
Published: 01 September 2022
View articletitled, First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response
Open the PDF for First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response in another window
Includes: Supplementary data
Journal Articles

Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules

Georgina V. Long, Caroline Robert, Marcus O. Butler, Felix Couture, Matteo S. Carlino, Steven O'Day, Victoria Atkinson, Jonathan S. Cebon, Michael P. Brown, Stéphane Dalle, Andrew G. Hill, Geoffrey T. Gibney, Steven McCune, Alexander M. Menzies, Cuizhen Niu, Nageatte Ibrahim, Blanca Homet Moreno, Adi Diab
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (19): 5280–5288.
https://doi.org/10.1158/1078-0432.CCR-21-0793
Published: 01 October 2021
View articletitled, Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules
Open the PDF for Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules in another window
Includes: Supplementary data
Journal Articles

The State of Melanoma: Emergent Challenges and Opportunities

Michael B. Atkins, Clara Curiel-Lewandrowski, David E. Fisher, Susan M. Swetter, Hensin Tsao, Julio A. Aguirre-Ghiso, Maria S. Soengas, Ashani T. Weeraratna, Keith T. Flaherty, Meenhard Herlyn, Jeffrey A. Sosman, Hussein A. Tawbi, Anna C. Pavlick, Pamela B. Cassidy, Sunandana Chandra, Paul B. Chapman, Adil Daud, Zeynep Eroglu, Laura K. Ferris, Bernard A. Fox, Jeffrey E. Gershenwald, Geoffrey T. Gibney, Douglas Grossman, Brent A. Hanks, Douglas Hanniford, Eva Hernando, Joanne M. Jeter, Douglas B. Johnson, Samir N. Khleif, John M. Kirkwood, Sancy A. Leachman, Darren Mays, Kelly C. Nelson, Vernon K. Sondak, Ryan J. Sullivan, Glenn Merlino
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (10): 2678–2697.
https://doi.org/10.1158/1078-0432.CCR-20-4092
Published: 15 May 2021
View articletitled, The State of Melanoma: Emergent Challenges and Opportunities
Open the PDF for The State of Melanoma: Emergent Challenges and Opportunities in another window
Journal Articles

Combined BRAF and HSP90 Inhibition in Patients with Unresectable BRAFV600E-Mutant Melanoma

Zeynep Eroglu, Y. Ann Chen, Geoffrey T. Gibney, Jeffrey S. Weber, Ragini R. Kudchadkar, Nikhil I. Khushalani, Joseph Markowitz, Andrew S. Brohl, Leticia F. Tetteh, Howida Ramadan, Gina Arnone, Jiannong Li, Xiuhua Zhao, Ritin Sharma, Lancia N.F. Darville, Bin Fang, Inna Smalley, Jane L. Messina, John M. Koomen, Vernon K. Sondak, Keiran S.M. Smalley
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (22): 5516–5524.
https://doi.org/10.1158/1078-0432.CCR-18-0565
Published: 15 November 2018
View articletitled, Combined BRAF and HSP90 Inhibition in Patients with Unresectable BRAFV600E-Mutant Melanoma
Open the PDF for Combined BRAF and HSP90 Inhibition in Patients with Unresectable BRAFV600E-Mutant Melanoma in another window
Includes: Supplementary data
Journal Articles

Safety, Correlative Markers, and Clinical Results of Adjuvant Nivolumab in Combination with Vaccine in Resected High-Risk Metastatic Melanoma

Geoffrey T. Gibney, Ragini R. Kudchadkar, Ronald C. DeConti, Melissa S. Thebeau, Maria P. Czupryn, Leticia Tetteh, Cabell Eysmans, Allison Richards, Michael J. Schell, Kate J. Fisher, Christine E. Horak, H. David Inzunza, Bin Yu, Alberto J. Martinez, Ibrahim Younos, Jeffrey S. Weber
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (4): 712–720.
https://doi.org/10.1158/1078-0432.CCR-14-2468
Published: 16 February 2015
View articletitled, Safety, Correlative Markers, and Clinical Results of Adjuvant Nivolumab in Combination with Vaccine in Resected High-Risk Metastatic Melanoma
Open the PDF for Safety, Correlative Markers, and Clinical Results of Adjuvant Nivolumab in Combination with Vaccine in Resected High-Risk Metastatic Melanoma in another window
Journal Articles

Conjunctival Melanomas Harbor BRAF and NRAS Mutations—Letter

Jaimie L. Weber, Keiran S.M. Smalley, Vernon K. Sondak, Geoffrey T. Gibney
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (22): 6329–6330.
https://doi.org/10.1158/1078-0432.CCR-13-2007
Published: 14 November 2013
View articletitled, Conjunctival Melanomas Harbor BRAF and NRAS Mutations—Letter
Open the PDF for Conjunctival Melanomas Harbor BRAF and NRAS Mutations—Letter in another window